Odronextamab Clinical Trials (2026): 16 Studies for Follicular Lymphoma (FL) & Refractory Diffuse Large B-Cell Lymphoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
16 Odronextamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 14 indications (including Follicular Lymphoma (FL) & Refractory Diffuse Large B-Cell Lymphoma) and 4,491 total planned enrollment. 5 Phase 3 Odronextamab trials and 4 Phase 2 are listed. 10 Odronextamab clinical trials are actively recruiting at 53 U.S. sites across 21 states. Most recent activity: NCT05991388 (May 2033).
Where to Participate: All Odronextamab Trial Sites in the U.S. (53 sites across 21 states)
Every actively recruiting Odronextamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | University of Arizona Cancer Center | Tucson85724 | NCT06091254 | Map |
| CA | City of Hope | Duarte91010 | NCT05685173 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06735664 | Map |
| CA | David Geffen School of Medicine at UCLA | Los Angeles90095 | NCT06091254 | Map |
| CA | David Geffen School of Medicine at UCLA | Los Angeles90095 | NCT06091865 | Map |
| CA | David Geffen School of Medicine at UCLA | Los Angeles90095 | NCT06149286 | Map |
| CA | University of California Irvine Medical Center | Orange92868 | NCT06091865 | Map |
| CA | University of California (UC) Davis | Sacramento95817 | NCT06091865 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06854159 | Map |
| CA | University of California Los Angeles (UCLA) Medical Center | Santa Monica90404 | NCT05685173 | Map |
| FL | Boca Raton Clinical Research (BRCR) Global | Plantation33322 | NCT06149286 | Map |
| IN | Indiana University and Comprehensive Cancer Center | Indianapolis46202 | NCT06149286 | Map |
| IN | Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis46202 | NCT06091865 | Map |
| IN | St Vincent Ascension at Peyton Manning Childrens Hospital | Indianapolis46260 | NCT06091865 | Map |
| IN | Investigative Clinical Research of Indiana | Noblesville46062 | NCT06091254 | Map |
| IN | Investigative Clinical Research of Indiana | Noblesville46062 | NCT06091865 | Map |
| KY | University of Kentucky | Lexington40536 | NCT06091865 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT05685173 | Map |
| MD | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore21201 | NCT06091865 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT07128641 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06091254 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06091865 | Map |
| MA | Harvard Medical School - Beth Israel Deaconess Medical Center | Boston02215 | NCT05685173 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05685173 | Map |
| MI | Henry Ford Health System | Detroit48202 | NCT06091865 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT06091254 | Map |
| MI | Cancer and Hematology Centers of Western Michigan | Grand Rapids49503 | NCT06091865 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT06975787 | Map |
| MS | Hattiesburg Clinic | Hattiesburg39401 | NCT06149286 | Map |
| NH | Dartmouth Cancer Center | Lebanon03756 | NCT06149286 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT05685173 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT06091865 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT05685173 | Map |
| NY | Icahn School of Medicine at Mt Sinai | New York10029 | NCT06091254 | Map |
| NY | NYU Langone Health Perlmutter Cancer Center | New York10016 | NCT05685173 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT06091254 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT06091865 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT06149286 | Map |
| NC | University of North Carolina | Chapel Hill27514 | NCT06091254 | Map |
| NC | Levine Cancer Institute | Charlotte28207 | NCT06091254 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06091865 | Map |
| NC | East Carolina University | Greenville27834 | NCT06091865 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06091254 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06091865 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT06091254 | Map |
| TX | UT Southwestern | Dallas75390 | NCT05685173 | Map |
| TX | Baylor College of Medicine | Houston77030 | NCT06975787 | Map |
| TX | Center for Oncology and Blood Disorders | Houston77030 | NCT06091254 | Map |
| UT | Community Cancer Trials of Utah | Ogden84405 | NCT06091865 | Map |
| UT | Huntsman Cancer Institute - Oncology Division | Salt Lake City84112 | NCT06091254 | Map |
| VA | University of Virginia | Charlottesville22908 | NCT06091254 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT06784726 | Map |
| WI | Prohealth Care Inc | Waukesha53188 | NCT06149286 | Map |
Odronextamab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | available | Total |
|---|---|---|---|---|---|
| P1 | 3 | 2 | 5 | ||
| P2 | 3 | 1 | 4 | ||
| P2/P3 | 1 | 1 | |||
| P3 | 3 | 2 | 5 | ||
| N/A | 1 | 1 |
Recruiting Odronextamab clinical trials (10)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05991388 | Glo-BNHLA Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | P2/P3 | B-cell Non Hodgkin Lymphoma | 210 | May 2024 |
| NCT06784726 | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | P2 | Recurrent Diffuse Large B-Cell Lymphoma | 27 | Sep 2025 |
| NCT05685173 | ATHENA-1A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas | P1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | 107 | Apr 2023 |
| NCT06091254 | OLYMPIA-1A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | P3 | Follicular Lymphoma (FL) | 822 | Dec 2023 |
| NCT06091865 | OLYMPIA-3A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | P3 | Diffuse Large B-cell Lymphoma (DLBCL) | 904 | Dec 2023 |
| NCT06975787 | Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis | P1 | Lupus Nephritis (LN) | 90 | Dec 2025 |
| NCT06854159 | Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy | P2 | Recurrent Diffuse Large B-Cell Lymphoma | 34 | Aug 2025 |
| NCT06149286 | OLYMPIA-5A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | P3 | Relapsed/Refractory Follicular Lymphoma | 470 | Dec 2023 |
| NCT07128641 | Odronextamab in Low Tumor Volume Advanced FL | P2 | Follicular Lymphoma | 35 | Sep 2025 |
| NCT06735664 | Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation | P1 | Recurrent Transformed Chronic Lymphocytic Leukemia | 23 | Aug 2025 |
Odronextamab clinical trials by indication
Recurrent Diffuse Large B-Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06784726 | — | P2 | recruiting | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T |
| NCT06854159 | — | P2 | recruiting | Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy |
Follicular Lymphoma (FL) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06091254 | OLYMPIA-1 | P3 | recruiting | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma |
| NCT06097364 | OLYMPIA-2 | P3 | active not recruiting | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma |
Lupus Nephritis (LN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06975787 | — | P1 | recruiting | Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis |
Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07128641 | — | P2 | recruiting | Odronextamab in Low Tumor Volume Advanced FL |
Recurrent Transformed Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06735664 | — | P1 | recruiting | Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation |
B-cell Non Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05991388 | Glo-BNHL | P2/P3 | recruiting | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma |
B-Cell Non-Hodgkin Lymphoma (B-NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06230224 | OLYMPIA-4 | P3 | active not recruiting | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma |
Relapsed/Refractory Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06149286 | OLYMPIA-5 | P3 | recruiting | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma |
Diffuse Large B-cell Lymphoma (DLBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06091865 | OLYMPIA-3 | P3 | recruiting | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma |
B-cell Non-Hodgkins Lymphoma (B-NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05685173 | ATHENA-1 | P1 | recruiting | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas |
B-cell Non-Hodgkin Lymphoma (B-NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03888105 | ELM-2 | P2 | active not recruiting | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies |
Relapsed/Refractory Aggressive B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02651662 | CLIO-1 | P1 | completed | A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies |
Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02290951 | ELM-1 | P1 | completed | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies |
Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05619367 | CU | N/A | available | A Compassionate Use (CU) Program of Odronextamab |
Odronextamab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| OLYMPIA-1 | NCT06091254 | P3 | recruiting | Follicular Lymphoma (FL) | 822 | — |
| OLYMPIA-3 | NCT06091865 | P3 | recruiting | Diffuse Large B-cell Lymphoma (DLBCL) | 904 | — |
| OLYMPIA-2 | NCT06097364 | P3 | active not recruiting | Follicular Lymphoma (FL) | 733 | — |
| OLYMPIA-4 | NCT06230224 | P3 | active not recruiting | B-Cell Non-Hodgkin Lymphoma (B-NHL) | 216 | — |
| OLYMPIA-5 | NCT06149286 | P3 | recruiting | Relapsed/Refractory Follicular Lymphoma | 470 | — |
| ELM-2 | NCT03888105 | P2 | active not recruiting | B-cell Non-Hodgkin Lymphoma (B-NHL) | 515 | — |
All Odronextamab trials (16)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05991388 | Glo-BNHL | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | P2/P3 | recruiting | 210 | University of Birmingham | May 2024 |
| NCT06784726 | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | P2 | recruiting | 27 | University of Washington | Sep 2025 | |
| NCT05685173 | ATHENA-1 | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas | P1 | recruiting | 107 | Regeneron Pharmaceuticals | Apr 2023 |
| NCT06091254 | OLYMPIA-1 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | P3 | recruiting | 822 | Regeneron Pharmaceuticals | Dec 2023 |
| NCT06091865 | OLYMPIA-3 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | P3 | recruiting | 904 | Regeneron Pharmaceuticals | Dec 2023 |
| NCT06975787 | Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis | P1 | recruiting | 90 | Regeneron Pharmaceuticals | Dec 2025 | |
| NCT06097364 | OLYMPIA-2 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma | P3 | active not recruiting | 733 | Regeneron Pharmaceuticals | Nov 2023 |
| NCT06230224 | OLYMPIA-4 | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | P3 | active not recruiting | 216 | Regeneron Pharmaceuticals | Feb 2024 |
| NCT06854159 | Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy | P2 | recruiting | 34 | University of California, Davis | Aug 2025 | |
| NCT06149286 | OLYMPIA-5 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | P3 | recruiting | 470 | Regeneron Pharmaceuticals | Dec 2023 |
| NCT03888105 | ELM-2 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies | P2 | active not recruiting | 515 | Regeneron Pharmaceuticals | Nov 2019 |
| NCT07128641 | Odronextamab in Low Tumor Volume Advanced FL | P2 | recruiting | 35 | Gottfried von Keudell, MD PhD | Sep 2025 | |
| NCT06735664 | Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation | P1 | recruiting | 23 | City of Hope Medical Center | Aug 2025 | |
| NCT02651662 | CLIO-1 | A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies | P1 | completed | 105 | Regeneron Pharmaceuticals | Jan 2016 |
| NCT02290951 | ELM-1 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | P1 | completed | 200 | Regeneron Pharmaceuticals | Jan 2015 |
| NCT05619367 | CU | A Compassionate Use (CU) Program of Odronextamab | — | available | 0 | Regeneron Pharmaceuticals | — |
Odronextamab clinical trials: frequently asked questions
- How many Odronextamab clinical trials are there?
- 16 Odronextamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 10 are actively recruiting participants. 2 are marked completed.
- Are Odronextamab clinical trials recruiting in 2026?
- Yes — 10 Odronextamab trials are actively recruiting in 2026, with 53 U.S. sites across 21 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Odronextamab being studied for?
- Odronextamab is being studied for Follicular Lymphoma (FL), Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkins Lymphoma (B-NHL), B-cell Non Hodgkin Lymphoma and 31 more. The trials are grouped by indication on this page.
- What phase is Odronextamab in?
- Odronextamab clinical trials span 5 Phase 3, 4 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Odronextamab clinical trials?
- The lead sponsor across the most Odronextamab trials is Regeneron Pharmaceuticals, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Odronextamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: